We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




C‐Peptide Associated with NAFLD Inflammatory Progression

By LabMedica International staff writers
Posted on 27 Sep 2019
Non-alcoholic fatty liver disease (NAFLD) is characterized by an abnormal accumulation of fat in the liver, due to causes other than excessive alcohol use. More...
NAFLD is a continuum of liver abnormalities, from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).

Adults with type 2 diabetes and higher C-peptide levels are more likely to develop simple nonalcoholic fatty liver disease and nonalcoholic steatohepatitis compared with those with lower levels. In contrast, those with higher C-peptide levels are less likely to have advanced fibrosis.

Scientists at Shanghai Jiao Tong University School of Medicine (Shanghai, China) conducted a cross-sectional study with 4,120 adults with type 2 diabetes from the Huangpu and Pudong Districts in Shanghai (mean age, 67 years; 56.5% women). C-peptide, total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, high- density lipoprotein (HDL) cholesterol, fasting plasma glucose, alanine aminotransferase and aspartate aminotransferase were measured from blood samples. The team also recorded waist circumference and blood pressure to establish the presence of metabolic syndrome and used ultrasound to evaluate steatosis.

The investigators reported that compared with those with C-peptide levels of 1.12 ng/mL or less, probable NASH was more likely to be identified in participants with C-peptide levels of at least 2.06 ng/mL (OR = 5.28) and those with levels between 1.53 and 2.05 ng/mL (OR = 3.95 and 1.13 and 1.52 ng/mL (OR = 1.91.) Simple NAFLD was more likely to be identified in those with C-peptide levels of at least 2.06 ng/mL (OR = 4.55) between 1.53 and 2.05 ng/mL (OR = 3.21) and between 1.13 and 1.52 ng/mL (OR = 2.08) compared with those with lower levels. The odds of inflammatory progression were 1.34 times higher for every standard deviation increase in C-peptide (OR = 1.34). Fibrosis status was evaluated using the NAFLD fibrosis score, which identified 485 participants with a probable presence of advanced fibrosis. The odds of were lower for those with C-peptide levels of at least 2.23 ng/mL ((OR = 0.59). They also found that fibrotic progression odds were lower for those with C-peptide levels of at least 2.23 ng/mL (OR = 0.74).

The authors concluded that significant but opposite associations between C‐peptide and inflammatory and fibrotic progression of NAFLD was observed. Understanding islet hormone changes during type 2 diabetes and differentiating the stage of NAFLD may help to personalize treatment strategies for NAFLD patients with type 2 diabetes. The study was originally published online on July 27, 2019, in the journal Diabetes Metabolism Research and Reviews.

Related Links:
Shanghai Jiao Tong University School of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.